Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

PHASE3CompletedINTERVENTIONAL
Enrollment

447

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Treatment Outcome
Interventions
DRUG

Vortioxetine

Vortioxetine tablets

DRUG

Escitalopram

Escitalopram tablets

DRUG

Placebo

Vortioxetine Placebo-matching capsules

Trial Locations (62)

Unknown

Birmingham

Tucson

Anaheim

Chino

Costa Mesa

Encino

Escondido

Irvine

Newport Beach

Oceanside

San Diego

Norwich

Washington D.C.

Coral Springs

Fort Myers

Gainesville

Jacksonville

Lauderhill

North Miami

Orlando

Sanford

West Palm Beach

Atlanta

Chicago

Joliet

Lake Charles

Shreveport

Gaithersburg

Towson

Boston

Weymouth

Flowood

Creve Coeur

St Louis

Toms River

Willingboro

Albuquerque

New York

Rochester

Staten Island

Cincinnati

Dayton

Toledo

Oklahoma City

Portland

Allentown

Philadelphia

Memphis

Austin

Dallas

Charlottesville

Seattle

Waukesha

Medicine Hat

Kelowna

Penticton

Sydney

Burlington

Chatham

Kingston

Mississauga

Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT01364649 - Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction | Biotech Hunter | Biotech Hunter